OVERVIEW
- All subgroups benefitted from pertuzumab
- Pertuzumab improved invasive disease-free survival (IDFS) in all subgroups, greatest in HER2 FISH-LOW/ER-positive tumours
- The findings support prospective validation of biomarker-guided strategies.
STUDY DETAILS
APHINITY was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.
The APHINITY trial was supported by F. Hoffmann-La Roche Ltd/Genentech and was designed by the Breast International Group (BIG) in collaboration with the sponsor.
The database was maintained at the Institut Jules Bordet Clinical Trials Support Unit (Brussels, Belgium), and the statistical analyses were carried out by Frontier Science Scotland.
TITLE OF PUBLICATION
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial
AUTHORS
Elisa Agostinetto, Gabriella Gentile, Faye Samy, Serena Di Cosimo, Philippe Aftimos, Noam Pondé, Daniel Eiger, Matteo Lambertini, David Cameron, Astrid Kiermaier, Andrew Bailey, Giuseppe Viale, Sherene Loi, Martine Piccart, Evandro de Azambuja.
JNCI. Publication Year 2026
